Max Crispin Mbiochem

Biography

Professor Max Crispin joined Biological Sciences from the Glycobiology Institute at the University of Oxford. He runs the Glycoprotein Therapeutics Laboratory which is predominantly focussed on developing anti-viral vaccines and new antibody-based therapies against cancer. Understanding the structure and function of glycoproteins and how they can be engineered offers exciting routes to the development of new vaccines and therapeutics Career History Sept 2017-present: Professor of Glycobiology. University of Southampton, UK. Oxford Glycobiology Institute, University of Oxford May 2013-Aug 2017: Principal Investigator, Glycoprotein Therapeutics Laboratory Dec 2011-Aug 2017: University Research Lecturer Feb 2009-May 2013: Senior Research Associate, Laboratory of Dr Chris Scanlan Corpus Christi College, Oxford Sep 2014-Aug 2017: Stipendiary Lectureship in Biochemistry, Director of Studies (Biochemistry) Oriel College, Oxford Feb 2017 - Aug 2017: Senior Dean Sep 2014 - Aug 2017: Against Breast Cancer Senior Research Fellow Sep 2008 - Aug 2014: Fellow and Tutor in Biochemistry

Research Interest

In the Glycoprotein Therapeutics Laboratory we exploit the glycan modifications of proteins in the design of vaccines candidates and glycoprotein-based therapeutics. We have a particular interest in vaccine design against the Human Immunodeficiency Virus (HIV) and in the development of novel antibody-based cancer therapeutics. This involves understanding how glycans impact on protein and viral function, how they are structured, and how we they can be manipulated for therapeutic applications.